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Background: After radical prostatectomy (RP) radiotherapy (RT) plays a role, both as adjuvant 
or salvage treatment. If negative features are present such as extracapsular extension, seminal 
vesicle invasion, lymph invasion, and positive surgical margins, RT after RP reduces the risk 
of recurrence, although it is associated with an increased risk of acute and late toxicities. An 
intensified RT delivered in a shortened time could improve clinical outcome and be safely 
combined with hormonal therapy (HT). The aim of this study was to determine the acute and 
late toxicities associated with hypofractionated RT and to assess the impact of the addition of 
HT to RT in high-risk prostate cancer (PC) patients on overall response and toxicity.
Materials and methods: Sixty-four PC patients undergoing RP were included in this retro-
spective study. All patients were recommended to receive adjuvant or salvage RT. Prescription 
doses were 62.5 Gy in 25 fractions to prostate bed, 56.25 Gy in 25 fractions to seminal vesicles 
bed, and 50 Gy in 25 fractions to pelvis if indicated. HT was administered to patients with 
additional adverse pathologic features including Gleason score >7, prostate-specific antigen 
>20 ng/mL before surgery, or prostate-specific antigen with rapid doubling time after relapse 
or nodal involvement. After completion of RT, patients were observed after 4 weeks, and then 
followed-up every 3–6 months. Acute and late toxicities were assessed using Common Terminol-
ogy Criteria for Adverse Events v4 and Radiation Therapy Oncology Group scale, respectively.
Results: For acute toxicity, only grade 1 gastrointestinal and genitourinary toxicities were detected 
in 17% and 11% of patients, respectively. As regards late toxicity, only 5% of the patients developed 
grade 1 gastrointestinal adverse event; grade 1, grade 2, and grade 3 genitourinary toxicity was 
recorded in 5%, 3.3%, and 3.3% of patients, respectively. Two and 5 years overall survival were 
98% and 96%, respectively. The curves stratified for treatment show a slight difference between 
patients receiving RT or RT+HT, but the differences did not reach statistical significance (p=0.133).
Conclusion: In patients with PC undergoing RP, hypofractionated RT may contribute to achieve 
a high overall survival with an acceptable toxicity profile. Combination of RT and HT is also 
well tolerated and efficacious.
Keywords: prostate cancer, postoperative radiotherapy, hypofractionation
Introduction
Prostate cancer (PC) represents one of the most frequent cancers worldwide along 
with breast, lung, and colon cancer.1 Patients with localized prostatic cancer are often 
treated with surgery, but more than 30% of tumors eventually recur. After surgery, 
radiotherapy (RT) plays a role, both as adjuvant or salvage treatment, if adverse features 
are present or if prostate-specific antigen (PSA) levels increase. Large randomized 
controlled trials addressing the role of postoperative RT have been completed.2–4 In 
Correspondence: Liliana Belgioia
University of Genoa-Ospedale Policlinico 
San Martino, Largo Rosanna Benzi, 10, 
16132 Genoa, Italy
Tel +39 010 5558 933
Email liliana.belgioia@unige.it 
Journal name: Cancer Management and Research
Article Designation: ORIGINAL RESEARCH
Year: 2018
Volume: 10
Running head verso: Barra et al
Running head recto: Hypofractionated radiotherapy post prostatectomy
DOI: http://dx.doi.org/
DocuSign Envelope ID: 7A627E7A-EBDF-49A2-8047-7626FB95B8C9
In Pro s
Cancer Management and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Barra et al
case of extracapsular extension, seminal vesicle invasion, 
lymph invasion, and positive surgical margins, RT after RP 
reduces the risk of recurrence. However, this is associated 
with an increase in acute and late toxic effects. Prospective 
studies comparing adjuvant and salvage RT are ongoing, and 
dose escalation, different RT techniques, and concomitant 
use of hormonal therapies (HT) are unsolved open questions.
Conventionally, RT is delivered with a standard prolonged 
fractionation of 2 Gy per single dose. Recently, hypofrac-
tionated RT, ie, shortening the overall treatment time by 
delivering an effective biological dose with single dose 
higher than 2 Gy, has been shown to maintain the clinical 
benefits of conventional RT, although it has been reported 
to be associated with a higher risk of acute and late effects. 
Thus, gastrointestinal (GI) and genitourinary (GU) toxici-
ties might be the main drawbacks of hypofractionated RT. 
The biological basis for a hypofractionated RT is that PC, 
compared to other cancers, has a lower α/β ratio (α and β 
are the parameters of radiosensitivity adopted in modeling 
formulae of fractionation).5–8 Tumors with a low α/β ratio 
may benefit from fractionated schedules with single doses 
above 2.4–2.6 Gy.9,10 Hypofractionated RT, when delivered 
with advanced technology (Image-guided Radiotherapy 
[IGRT] and Intensity-modulated Radiotherapy [IMRT]), has 
the potential to limit GI and GU toxicities, although initial 
experiences gave controversial outcomes.11,12 On a positive 
note, hypofractionated RT has lower costs in an RT depart-
ment and is much more convenient for patients.
In locally advanced PC, a significant proportion of 
patients progress following RT alone regardless of fraction-
ated schedule.13–15 In this setting, patients at high risk (ie, 
those with high Gleason score or high PSA levels) may 
benefit from the addition of HT, as suggested by several 
trials and two meta-analyses showing decreased mortality 
and recurrence with an acceptable toxicity.13–15 Recently, a 
randomized study showed that the addition of antiandrogenal 
therapy to salvage radiation therapy resulted in higher rates 
of long-term overall survival (OS) and low incidences of 
metastasis cancer.16
It is still unclear whether the addition of HT to shortened 
hypofractionated RT provides a good profile of compliance 
beyond the excellent biochemical disease control and OS.
We here report the results of a retrospective study on 
the moderate hypofractionated RT after prostatectomy. Our 
primary aim was to determine the acute and late toxicities 
associated with hypofractionated RT; second, we analyzed 
if the addition of HT in high-risk PC patients was associated 
with a better overall response and toxicity profile compared 
to those of patients receiving RT alone.
Materials and methods
Patients
Between 2010 and 2016, 64 patients with PC undergoing 
radical prostatectomy (RP) were recommended to receive 
adjuvant or salvage RT for adverse pathologic features 
including extracapsular extension, invasion of the seminal 
vesicles, and positive margins. Patients underwent pelvic 
RT if there was presence of positive pelvic nodes or in those 
with a risk (>15%) of pelvic nodal involvement, according 
to Roach formula.17 In addition, RT was recommended in 
those patients experiencing a postprostatectomy raise in PSA 
that was undetectable before surgery. Androgen deprivation 
therapy was administered in the presence of adverse patho-
logic features including Gleason score >7, PSA >20 ng/mL 
before surgery, or PSA with rapid doubling time after relapse 
or nodal involvement. Before RT, all patients underwent mul-
tiparametric prostate magnetic resonance imaging. Patients 
with clinical recurrence in the prostate bed or with clinical 
positive lymph nodes after surgery were excluded from the 
study. This retrospective data analysis was approved by the 
Steering Ethical Committee of the IRCCS Policlinico San 
Martino, Genoa, Italy. All patients signed an informed writ-
ten consent.
The main characteristics of the patients are reported in 
Table 1.
Treatment
Patients were treated with Helical Tomotherapy (Accuray, 
Sunnydale, CA, USA) or volumetric-modulated arc therapy 
using VMAT technique delivered by a High-Tech Linear 
Accelerator (Varian RapidArc, Palo Alto, CA, USA). All 
patients underwent computed tomographic (CT) simulation 
with a full bladder and empty rectum, in the supine position 
placed in an appropriate fixation device (Combifix, Civco 
Medical Solutions, Coralville, IA, USA). CT data sets 
were sent for contouring on the Eclipse treatment planning 
system (VarianMedical System, Palo Alto, CA, USA) and 
then exported using DICOM RT (digital imaging and com-
munication in medicine) format to Tomotherapy Planning 
System or directly to the treatment with the Trilogy Linear 
Accelerator. For all patients, Clinical Target Volume 1 
(CTV) consisted of prostate bed, CTV2 the seminal vesicles 
bed, and CTV3 included, obturator, presacral, external and 
internal lymph nodes to below the aortic bifurcation. The 
DocuSign Envelope ID: 7A627E7A-EBDF-49A2-8047-7626FB95B8C9
In Pro s
Cancer Management and Research 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3
Hypofractionated radiotherapy post prostatectomy
CTV1 was contoured using Radiation Therapy Oncology 
Group consensus guidelines,18 modified according to surgi-
cal and pathologic findings. The planning target volume 1 
(PTV1) was obtained adding a margin of 5 mm posteriorly 
and 7 mm in all other directions to CTV1; PTV2 and PTV3 
were obtained adding a 5 mm isotropic margin to CTV2 
and CTV3.
Rectum, bladder, femoral heads, large and small bowel, 
and penile bulb were outlined as organs at risk. The course 
of radiotherapy consisted of 25 fractions of 2.5 Gy daily for 
a total dose of 62.5 Gy to PTV1. The volume of the seminal 
vesicles received a total dose of 56.25 Gy in 25 fractions, 
2.25 Gy daily. If pelvic nodes were irradiated, a total dose of 
50 Gy in 25 fractions with a single dose of 2 Gy per fraction 
was delivered.
The dose was calculated with the normalized total 
dose formula considering a prostate α/β ratio of 1.5 Gy. 
Dose– volume histogram (DVH) goals for the rectum were 
V40≤43%, V50≤32%, and V65≤10%. The bladder DVH goals 
were V40≤47%, V55≤27%, and V60≤14%. The femoral head 
DVH goal was V20<50%; a constraint to the bowel placed 
out of the PTV was accepted with a mean dose of 19.8 Gy, 
while for penile bulb, the median dose was set to 39 Gy. 
Megavoltage CT by HT or Cone-Beam CT by Trilogy was 
performed every day before treatment to correct patient setup 
according to bone and soft tissue anatomy and to take into 
account the intrafraction variability.
Patients were treated every day following a rectum and 
bladder institutional protocol that strongly recommended 
empty rectum and drinking 500 mL of water 30 minutes 
before each RT fraction after having emptied the bladder. If 
patients had unacceptable bladder or rectal filling, the treat-
ment was deferred until correct filling volumes were reached.
HT was started the first day of RT and consisted of 
gonadotropin-releasing hormone agonists or antiandrogen 
therapy, according to the physician’s decision.
Follow-up and toxicity evaluation
After completion of RT, patients were observed after 4 
weeks, then every 3–6 months for physical examination, PSA 
measurement, and assessment of toxicity. Acute toxicities 
were retrospectively graded based on physicians’ notes dur-
ing treatment using the Common Terminology Criteria for 
Adverse Events version 4.0. Late toxicities were defined as 
those occurring 6 months after RT and were scored using the 
Radiation Therapy Oncology Group and European Organiza-
tion for Research and Treatment of Cancer Scale.
Statistical analysis
A descriptive analysis was done in which clinical and 
demographic variables were compared in patients with PC 
receiving RT or RT+HT, after RP.
For categorical variables, the numbers and percentages 
are reported, while for continuous variables the mean and SD 
values are considered. The p-values were calculated using the 
χ2 test for the categorical variables and the Kruskal–Wallis 
test for the continuous variables.
The survival curves, stratified for the different clinical 
variables, were obtained using the Kaplan–Meier method. 
The Kaplan–Meier method followed by a multivariate Cox 
model was used to analyze the toxicity following RT, distin-
guishing between acute and late toxicity.
Results
Patients characteristics
Sixty four men with median age 68 years (range, 48–82) 
were treated with hypofractionated RT after prostatectomy. 
The median follow-up of the entire patient population was 
15.5 months (range, 3–64 months).
Thirty two patients were treated with adjuvant RT and 
32 with salvage RT. Pre-RT median PSA was 0.205 ng/mL 
(range, 0.003–5.46 ng/mL) in the adjuvant setting and 0.23 
ng/mL (range, 0.009–5.48 ng/mL) in the salvage treatment. 
Table 1 Main characteristics of the patients analyzed
Patient characteristic All Patients RT RT+HT P-value
Number of patients (%) 64 33 (51.5) 31 (48.5)
Number of deaths (%) 2 0 (0.0) 2 (6.5)
Age at surgery, mean (SD) 64.9 64.7 (6.8) 64.2 (8.2) 0.995
Gleason score >7, N (%) 27 (42.2) 9 (27.3) 18 (58.1) 0.013
PSA levels before surgery, ng/mL, mean (SD) 11.9 8.9 (5.5) 11.8 (6.7) 0.047
Comorbidity (<1), N (%)a 25 11 (33.3) 14 (45.2) 0.332
Positive lymph nodes (≥1), N (%) 16 0 (0.0) 16 (51.6) <0.0001
Notes: aCardiovascular disease, arterial hypertension, bowel disease, diabetes mellitus.
Abbreviations: HT, hormonal therapy; PSA, prostate-specific antigen; RT, radiotherapy.
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Median time between surgery and the start of RT was 7 
months (range, 3–149).
Sixteen patients were pathological node stage (pN+) (12 
in adjuvant, 4 in salvage group), 18 pathological tumor stage 
(pT)3a (11 in adjuvant, 7 in salvage), 25 pT3b (16 in adju-
vant, 9 in salvage), and 5 microscopic residual disease (R1).
Two patients died of causes unrelated to PC. At the time 
of analysis, no patients had a biochemical relapse. The OS 
of the whole study group was >98% at 24 months.
Thirty-eight patients were irradiated in the pelvic area, 
15 (40%) in the adjuvant and 23 (60%) in the salvage RT 
group. HT was administered in 18 and 13 patients undergo-
ing, respectively, adjuvant and salvage RT. Gonadotropin-
releasing hormone agonists were prescribed in 26 patients 
(84%), while 5 (16%) received antiandrogens. Median HT 
time was 12 months (range, 1–62 months), and 19/31 patients 
were still on HT at the time of last follow-up.
Table 1 reports the clinical pathological characteristic of 
the two patient populations (RT and RT+HT). Mean age at 
surgery and comorbidity were similar between the two groups. 
A higher percentage of patients treated with RT+HT had a 
Gleason score >8 (58.1% vs 27.3%) and more frequently had 
more positive lymph nodes compared to those receiving RT 
only (21.6% vs 0%); in addition, higher PSA levels before 
surgery were observed in RT+HT treated patients.
Toxicity evaluation
As regards acute toxicity, only grade 1 GI and GU toxicities 
were detected in 11 (17%) and 7 (11%) patients, respectively. 
About 61 out of 64 patients (95%) were evaluable for late 
toxicity; 3 patients were excluded because of follow-up 
duration being less than 6 months. Three of 61 patients (5%) 
developed grade 1 GI adverse event; grade 1, grade 2, and 
grade 3 GU was recorded in 3 (5%), 2 (3.3%), and 2 (3.3%) 
patients, respectively.
A higher incidence of acute toxicity was observed for 
patients receiving pelvic irradiation (p=0.0019); a similar 
trend, although not reaching a statistically significant differ-
ence (p=0.07), was observed for late toxicity.
The overall late toxicity rate at 5 years was 73.1% 
( Figure 1A). When the “toxicity-free survival” was stratified 
for the treatment received, it seems that patients receiving 
RT+HT had a slightly lower toxicity-free survival compared 
to those receiving RT only, although the differences were not 
statistically significant. In fact, the Log-rank test P-value 
comparing RT vs RT+HT was 0.247 (Figure 1B). A similar 
trend was found for acute toxicity (Figure 1C and D).
The results of the multivariate analysis (Cox model) 
are reported in Table 2 for the acute toxicity and in Table 3 
for the late toxicity. Patients with 1 or more lymph nodes 
have an increased risk (97 fold) of acute toxicity relative 
to patients with no positive lymph nodes. Pre-RT PSA 
values, as well as age, type of treatment (RT or RT+HT), 
or presence of comorbidities did not impact on the risk 
to develop acute toxicity. A trend, although not reaching 
a statistical significance (p=0.094), was observed when 
presurgery PSA levels are considered: an increase of 1 
unit in the PSA value is associated with a 7% increased 
risk of acute toxicity.
When late toxicity was considered, again patients with 1 
or more comorbidities have a statistically significant lower 
risk (96%) of experiencing late toxicity relative to patients 
with no comorbidities (p=0.024). Presurgery or pre-RT PSA 
values as well as type of treatment (RT or RT+HT) did not 
impact the development of late toxicity. A trend, although not 
reaching a statistical significance, was observed when age 
was considered: an increase of 1 year of age is associated 
with an increased risk of late toxicity of 17%.
Considering the OS of the 64 patients under study, at 
60 months there was a high probability of survival (>96%) 
(Figure 2A). Having registered only 2 deaths (all in the group 
of patients receiving RT+HT), the curves stratified for treat-
ment reported in Figure 2B show a slight difference between 
patients receiving RT or RT+HT, although the differences did 
not reach statistical significance (p=0.133).
The survival curves stratified for the variables found sta-
tistically different between the two groups (RT vs RT+HT) 
are reported in Figure 2C and D. As can be seen, the presence 
of at least one positive lymph node reduces the probability to 
survive (Log-rank test p<0.001, Figure 2C). In patients with 
preexisting PSA levels <10, a better survival, compared to 
those patients with PSA values ≥10, was found (Figure 2D, 
Log-rank test p=0.071).
Discussion
Approximately 25% of patients with PC are primary treated 
with RP. One third of these patients are likely to show tumor 
recurrence after surgery.19,20 An increasing risk of recurrence 
is observed in patients with high Gleason score and positive, 
margins and these patients benefit from a postsurgery RT. 
In fact, adjuvant RT has been demonstrated to both increase 
progression-free survival (PFS) in different randomized trials 
and, in one of these trials, also to increase OS.2–4 In these stud-
ies, the median RT dose delivered to patients was 60–64 Gy. 
A retrospective study on 334 patients undergoing adjuvant 
RT showed that patients treated with ≥70 Gy had significantly 
improved biochemical PFS and cancer-specific survival rates 
compared with those receiving ≤70 Gy at median follow-up 
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of 108 months.21 Other studies confirmed these results, and 
two systematic reviews reported a 2% improvement in PFS 
for each additional Gy delivered.22,23 The SAKK 09/10 study 
is a trial where patients in biochemical failure after prostatec-
tomy but without evidence of macroscopic disease are ran-
domly assigned to 64 or 70 Gy, and preliminary results show 
that dose-intensified salvage radiation therapy is associated 
with low rates of acute grade 2 and 3 GU and GI toxicity.24
Due to the biological characteristic of PC, an advantage 
in terms of benefits and toxicity (as well as in costs) can 
Figure 1 Kaplan–Meier toxicity-free survival estimates. 
Notes: (A) Late toxicity-free survival in the overall population; (B) late toxicity-free survival stratified for treatment received (RT, black line vs RT+HT, gray line); (C) acute 
toxicity-free survival in the overall population; (D) acute toxicity-free survival stratified for treatment received (RT, black line vs RT+HT, gray line).
Abbreviations: HT, hormonal therapy; RT, radiotherapy.
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Table 2 Multivariate analysis (Cox model) for acute toxicity
Covariate HR SE z p>z 95% Confidence interval
RT+HT 0.382 0.385 –0.95 0.340 0.053–2.752
1+ Comorbidities 0.913 0.742 –0.11 0.910 0.185–4.495
Gleason score >8 0.206 0.180 –1.81 0.070 0.037–1.140
1+ Positive lymph nodes 19.897 24.661 2.41 0.016 1.753–225.81
RT-salvage 3.696 2.624 1.84 0.066 0.919–14.861
Pre-RT PSA 1.433 0.281 1.83 0.067 0.975–2.104
Presurgery PSA 1.066 0.041 1.68 0.094 0.989–1.150
Age 1.018 0.042 0.43 0.665 0.939–1.103
Pelvic RT 9.427 10.835 1.95 0.051 0.990–89.689
Abbreviations: HR, hazard ratio; HT, hormonal therapy; PSA, prostate-specific antigen; RT, radiotherapy; SE, standard error of the mean.
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been obtained with hypofractionated RT. The available data 
on hypofractionated RT in adjuvant or salvage setting is 
mainly based on retrospective studies.8,25–28 In these stud-
ies, single doses from 2.4 to 3 Gy, delivered with IMRT/
IGRT technique, were associated with low rates of grade 3 
acute GI and GU toxicities.29 Alongi et al11 evaluated 172 
patients undergoing whole-pelvis three-dimensional con-
formal radiotherapy (3D-CRT) versus IMRT and reported a 
lower risk of acute GI toxicity in the latter group. Similarly, 
another study30 showed a reduction in the risk of late grade 
2 or higher GI toxicity in men receiving IMRT compared to 
those treated with 3D-CRT, even if IMRT was not associated 
Figure 2 Kaplan–Meier survival estimates in the overall population (A), or stratified for: (B) treatment received (RT, black line vs RT+HT, gray line); (C) presence of at 
least one positive lymph node (0, black line vs 1+, gray line); (D) PSA value (<10, black line vs ≥10, gray line).
Abbreviations: HT, hormonal therapy; PSA, prostate-specific antigen; RT, radiotherapy.
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Table 3 Multivariate analysis (Cox model) for late toxicity
Covariate HR SE z p>z 95% confidence interval
RT+HT 9.722 33.238 0.67 0.506 0.011–7903.112
1+ Comorbidities 0.036 0.065 –1.85 0.064 0.001–1.206
Gleason score >8 0.032 0.048 –2.26 0.024 0.001–0.636
1+ Positive lymph nodes 5.565 19.662 0.49 0.627 0.005–5655.815
RT-salvage 0.0157 0.058 –1.13 0.260 0.00001–21.735
Pre-RT PSA 0.138 0.218 –1.25 0.210 0.006–3.048
Presurgery PSA 1.135 0.095 1.51 0.131 0.962–1.340
Age 1.169 0.099 1.83 0.067 0.988–1.382
Abbreviations: HR, hazard ratio; HT, hormonal therapy; PSA, prostate-specific antigen; RT, radiotherapy; SE, standard error of the mean.
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with a reduction in risk of grade ≥2 GU toxicity (5-yr IMRT, 
16.8%; 5-yr 3D-CRT, 15.8%; p=0.86), urinary incontinence 
(5-yr IMRT, 13.6%; 5-yr 3D-CRT, 7.9%; p=0.25), or grade 
3 erectile dysfunction (5-yr IMRT, 26%; 5-yr 3D-CRT, 
30%; p=0.82). Cozzarini et al12 reported, after a median 
follow-up of 98 months, a 5-yr risk of late urinary toxici-
ties of 6.9% and 18.1% in the conventionally fractionated 
and hypofractionated cohorts, respectively. In univariate 
analysis, the risk of late GU toxicity was predicted by dose 
per fraction, acute grade ≥2 toxicity, and year of irradiation. 
On multivariate analyses, acute grade ≥2 toxicity and dose 
per fraction independently predicted late adverse effects.
In the present analysis, although the follow-up is still 
short, the results of acute and late toxicity seem to confirm 
the feasibility of moderate hypofractionation when IMRT 
and IGRT are used.
There is also compelling evidence that adjuvant HT in 
combination with RT is indicated for patients with interme-
diate- or high-risk PC. The duration of HT depends on the 
risk category and can be short (4–6 months) for patients at 
intermediate risk and long (2 years and more) for patients 
with high risk.31–34
In this retrospective study, we also compared the effects 
of RT and RT+HT in patients undergoing RP in terms of OS 
and “toxicity-free” survival. The overall results are very posi-
tive with a high survival rate at 5 years (>95%). Among the 
64 patients studied, only two deaths occurred, both recorded 
in the RT+HT group. The high proportion of survival was 
associated with a low toxicity profile. Our study indicates the 
feasibility of hypofractionated RT due to its the low toxicity, 
which was only slightly increased when combined with HT.
The group of patients receiving the combination of RT 
and HT was the one with higher risk factors (a higher Gleason 
score, a higher level of presurgery PSA, and a presence of 
positive lymph nodes) compared to the group treated with RT 
only. The presence of high-risk factors justifies the addition 
of HT to RT and can explain the somehow increased risk of 
toxicity and slightly lower survival of this group relative to 
RT alone observed in the present study. It is to be pointed out 
that even in the presence of high negative prognostic factors, 
the OS of this group is still very good. The lack of a direct 
comparison in this study of a population with similar risk 
factors does not allow a proper comparison of the benefits 
of adding HT to RT. However, considering the high survival 
rate and the relatively low toxicity, it can be assumed that 
HT has an added value in terms of benefits for this category 
of patients.
Extrapolating some of the results of this study, it seems 
that for the acute toxicity, there is a trend of an increased risk 
of toxicity with age. This does not occur when late toxicity 
is considered. Since these results did not reach statistical 
significance, probably due to the small patient size, is dif-
ficult to speculate on their role, and so a more appropriate 
study on a larger population to specifically address these 
points is warranted.
Conclusion
In conclusion, we present evidence that in patients with 
PC undergoing RP, hypofractionated RT may contribute to 
achieve a high OS with an acceptable toxicity profile, even 
if a longer follow-up is needed to confirm these data. Com-
bination of RT and HT is also well tolerated and efficacious.
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